Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Lancet Rheumatol ; 4(5): e307-e308, 2022 May.
Article in English | MEDLINE | ID: covidwho-1937375
7.
The Lancet. Rheumatology ; 2022.
Article in English | EuropePMC | ID: covidwho-1749352
10.
Clin Gastroenterol Hepatol ; 20(7): 1609-1612.e1, 2022 07.
Article in English | MEDLINE | ID: covidwho-1611654

ABSTRACT

Patients with inflammatory bowel disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of their immunosuppression status. Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD; however, their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that patients with IBD on various therapies had detectable antibody responses after standard vaccinations.1-5 To date, one study has examined the kinetics of antibody response at 3 months after vaccination in patients with IBD, but data beyond this time point are not yet available.6 The aim of this study was to assess anti-spike antibody response 6 months after completion of standard SARS-CoV-2 vaccination in patients with IBD. Secondarily, we observed antibody kinetics over 6 months in a subset of patients post-vaccination.


Subject(s)
COVID-19 , Inflammatory Bowel Diseases , Viral Vaccines , Antibody Formation , COVID-19/prevention & control , COVID-19 Vaccines , Humans , Inflammatory Bowel Diseases/drug therapy , RNA, Messenger , SARS-CoV-2 , Vaccination , Viral Vaccines/genetics
16.
Arthritis Rheumatol ; 74(1): 28-32, 2022 01.
Article in English | MEDLINE | ID: covidwho-1340236

ABSTRACT

OBJECTIVE: To evaluate disease flare and postvaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following 2-dose SARS-CoV-2 messenger RNA (mRNA) vaccination. METHODS: RMD patients (n = 1,377) who received 2-dose SARS-CoV-2 mRNA vaccination between December 16, 2020 and April 15, 2021 completed questionnaires detailing local and systemic reactions experienced within 7 days of each vaccine dose (dose 1 and dose 2), and 1 month after dose 2, detailing any flares of RMD. Associations between demographic/clinical characteristics and flares requiring treatment were evaluated using modified Poisson regression. RESULTS: Among the patients, 11% reported flares requiring treatment; there were no reports of severe flares. Flares were associated with prior SARS-CoV-2 infection (incidence rate ratio [IRR] 2.09, P = 0.02), flares in the 6 months preceding vaccination (IRR 2.36, P < 0.001), and the use of combination immunomodulatory therapy (IRR 1.95, P < 0.001). The most frequently reported local and systemic reactions included injection site pain (87% after dose 1, 86% after dose 2) and fatigue (60% after dose 1, 80% after dose 2). Reactogenicity increased after dose 2, particularly for systemic reactions. No allergic reactions or SARS-CoV-2 diagnoses were reported. CONCLUSION: Flares of underlying RMD following SARS-CoV-2 vaccination were uncommon. There were no reports of severe flares. Local and systemic reactions typically did not interfere with daily activity. These early safety data can help address vaccine hesitancy in RMD patients.


Subject(s)
/adverse effects , COVID-19/prevention & control , Musculoskeletal Diseases/immunology , Rheumatic Diseases/immunology , /administration & dosage , Adult , COVID-19/immunology , Female , Humans , Male , Middle Aged , Prospective Studies , SARS-CoV-2/immunology , Symptom Flare Up
17.
Lancet Rheumatol ; 3(9): e607-e609, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1301110
SELECTION OF CITATIONS
SEARCH DETAIL